Kisaco Research, a U.K. event organizer, announced that leading experts in microbiome drug development will gather in Seoul on May 17-18 at Microbiome Connect Asia to share the latest research and developments in the industry.

Microbiome Connect is a global series of conferences dedicated to advancing the field of microbiome research and development in Europe, Asia, and North America.

The must-attend conference this year will feature keynote presentations from experts at the forefront of microbiome therapeutic development. 

Among the distinguished invited speakers are Genome & Company's CEO Pae Ji-soo, Arranta Bio Chief Scientific Officer Aaron Cowley, and BiomeBank CEO Sam Costello.

The conference will touch on topics such as managing manufacturing requirements for live biotherapeutic products (LBPs), the path to commercialization of microbiome therapeutics, and the use of microbiome therapeutics to treat diseases such as autism, cancer, and NASH.

Biotech leaders and microbiome researchers will have the opportunity to learn from the best in the field, network with industry peers and experts, and stay up to date on the latest trends and developments in microbiome research and development. 

Attendees will also gain insight into how to apply cutting-edge microbiome research in their work and organizations.

“Building on the success of Microbiome Connect in Europe & USA and following BiomeBank’s world-first approval for fecal transplants in Australia, I look forward to two days of stimulating discussion around the latest scientific breakthroughs at Microbiome Connect: Asia this May,” said Microbiome Connect Portfolio Director Jessica Thomson, who works at Kisaco Research. “We’re dedicated to driving innovation and growth in this industry, and we believe this conference is a pivotal step forward in advancing microbiome R&D across the region as we define the future of microbiome therapeutics.”

Those who wish to participate can register by visiting their website.